<i id='66175F76CE'><strike id='66175F76CE'><tt id='66175F76CE'><pre id='66175F76CE'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel
read more
PauloAmorim/VWPicsviaAPImagesLONDON—TwodaysaftersimilardecisionsintheU.S.andU.K.,regulatorsinEuropeo
read more
SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We
read moreAdobeDewpointTherapeutics,thebuzzieststartuptryingtotackleanewfieldofbiologycalledbiomolecularconden
